Difüz Tip Gastrik Kanserlerin 18F-FDG PET/CT ve Klinikopatolojik Verilerinin İncelenmesi

Amaç: Kansere bağlı ölümlerin önde gelen nedenlerinden biri olan mide kanserinin alt tiplerinden biri de diffüz tip mide kanseridir. Çalışmamızda mide kanseri tanı ve takibinde sıklıkla kullanılan bir görüntüleme yöntemi olan F-18 ile işaretli florodeoksiglukoz Pozitron emisyon tomografisinin, diffüz tip mide kanseri alt tiplerinde sonuçlarının retrospektif olarak araştırılması ve literatür ışığında gözden geçirilmesi amaçlanmıştır.

Anahtar Kelimeler:

Diffüz tip, Mide kanseri, Taşlı Yüzük Hücresi, Zayıf kohezif, 18F-FDG PET/CT

INVESTIGATION OF 18F-FDG PET / CT AND CLINICOPATHOLOGICAL DATA OF DIFFUSE TYPE GASTRIC CANCERS

Objective: One of the subtypes of stomach cancer, which is one of the leading causes of cancer-related deaths, is diffuse-type stomach cancer. In our study, it was aimed to retrospectively investigate the results of F-18-labeled fluorodeoxyglucose positron emission tomography, which is an imaging method frequently used in the diagnosis and follow-up of gastric cancer, in diffuse type gastric cancer subtypes and to review patient data in the light of the literatüre

Keywords:

Diffuse type, Gastric cancer, Poorly cohesive, Signet-Ring Cell, 18F-FDG PET/CT,

PDF

___

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
2. Lauren P. The two histological main types of gastric carcinoma: diffuse and so‐called intestinal‐type carcinoma: an attempt at a histo‐clinical classification. Acta Pathol Microbiol Scand. 1965;64(1):31-49.
3. Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250(6):878-87.
4. Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21(40):11428-38.
5. Kim J, Lim ST, Na CJ, Han YH, Kim CY, Jeong HJ et al. Pretreatment F-18 FDG PET/CT parameters to evaluate progression-free survival in gastric cancer. Nucl Med Mol Imaging. 2014;48(1):33-40.
6. Wang C, Guo W, Zhou M, Zhu X, Ji D, Li W et al. The predictive and prognostic value of early metabolic response assessed by positron emission tomography in advanced gastric cancer treated with chemotherapy. Clin Cancer Res. 2016;22(7):1603-10.
7. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38-v49.
8. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006;9(3):192-6.
9. Pak KH, Yun M, Cheong J-H, Hyung WJ, Choi SH, Noh SH. Clinical implication of FDG–PET in advanced gastric cancer with signet ring cell histology. J Surg Oncol. 2011;104(6):566-70.
10. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40(2):290-301.
11. Na SJ, Joo Hyun O, Park JM, Lee HH, Lee SH, Song KY et al. Prognostic value of metabolic parameters on preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III gastric cancer. Oncotarget. 2016;7(39):63968.
12. Chen J, Cai R, Ren G, Zhao J, Li H, Guo C et al. Differences in clinicopathological characteristics and computed tomography findings between signet ring cell carcinoma and nonsignet ring cell carcinoma in early and advanced gastric cancer. Cancer Med. 2018;7(4):1160-9.
13. Lauwers G, Carneiro F, Graham D, Curado M, Franceschi S, Montgomery E. WHO Classification of Tumours of the Digestive System. 3rd chapter, 4th ed. Lyon. IARC Publication, 2010:48-58.
14. Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J et al. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. Plos One. 2017;12(8):e0182692.
15. Kwon HR, Pahk K, Park S, Kwon HW, Kim S. Prognostic Value of Metabolic Information in Advanced Gastric Cancer Using Preoperative 18F-FDG PET/CT. Nucl Med Mol Imaging. 2019;53(6):386-95.
16. Liu G, Hu Y, Cheng X, Wang Y, Gu Y, Liu T et al. Volumetric parameters on 18 F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET. BMC Cancer. 2019;19(1):1-9.
17. Stahl A, Ott K, Weber W, Becker K, Link T, Siewert JR et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003;30(2):288-95.
18. Maman A, Sahin A, Ayan AK. The Relationship of SUV Value in PET-CT with Tumor Differentiation and Tumor Markers in Gastric Cancer. Eurasian J Med. 2020;52(1):67-72.
19. Alakus H, Batur M, Schmidt M, Drebber U, Baldus SE, Vallböhmer D et al. Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun. 2010;31(6):532-38.
20. Park YM, Kim JH, Baik SJ, Park JJ, Youn YH, Park H. Clinical risk assessment for gastric cancer in asymptomatic population after a health check-up: An individualized consideration of the risk factors. Medicine. 2016;95(44):e5351.
21. Yang HJ, Kang D, Chang Y, Ahn J, Ryu S, Cho J et al. Diabetes mellitus is associated with an increased risk of gastric cancer: a cohort study. Gastric Cancer. 2020;23(3):382-90.